Visually cued fear conditioning test for memory impairment related to cortical function.
fear conditioning
gratings
magnocellular
neocortex
visual cortex
Journal
Neuropsychopharmacology reports
ISSN: 2574-173X
Titre abrégé: Neuropsychopharmacol Rep
Pays: United States
ID NLM: 101719700
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
18
07
2020
revised:
26
08
2020
accepted:
15
09
2020
pubmed:
23
10
2020
medline:
8
9
2021
entrez:
22
10
2020
Statut:
ppublish
Résumé
Fear conditioning tests are intended to elucidate a subject's ability to associate a conditioned stimulus with an aversive, unconditioned stimulus, such as footshock. Among these tests, a paradigm related to precise cortical functions would be increasingly important in drug screening for disorders such as schizophrenia and dementia. Therefore, we established a new fear conditioning paradigm using a visual cue in mice. In addition, the validity of the test was evaluated using a genetically engineered mouse, heterozygous deficient in Mdga1 (Mdga1+/-), which is related to schizophrenia. Mice were given footshocks associated with a visual cue of moving gratings at training in 25-minute sessions. The mice showed the conditioned response of freezing behavior to the visual stimulus at testing 24 hours after the footshocks. In the test for validation, the Mdga1+/- deficient mice showed significantly less freezing than wild-type mice. The visually cued fear conditioning paradigm with moving gratings has been established, which is experimentally useful to evaluate animal cortical functions. The validity of the test was confirmed for Mdga1-deficient mice with possible deficiency in cortical functions.
Identifiants
pubmed: 33089673
doi: 10.1002/npr2.12146
pmc: PMC7722643
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
371-375Informations de copyright
© 2020 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Society of NeuropsychoPharmacology.
Références
Neurosci Lett. 2020 Jan 18;716:134677
pubmed: 31812551
J Neurosci. 2008 Jul 23;28(30):7492-500
pubmed: 18650327
Nat Protoc. 2006;1(3):1306-11
pubmed: 17406415
Dev Dyn. 2011 Jan;240(1):96-107
pubmed: 21104742
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):336-41
pubmed: 23248271
Vision Res. 1999 Sep;39(18):3071-81
pubmed: 10664805
Am J Med Genet B Neuropsychiatr Genet. 2008 Oct 5;147B(7):1089-100
pubmed: 18384059
Eur J Neurosci. 2012 Sep;36(6):2801-11
pubmed: 22738127
Science. 2018 Jun 22;360(6395):1349-1354
pubmed: 29930137
Learn Mem. 2004 Nov-Dec;11(6):686-96
pubmed: 15576886
J Vis Exp. 2014 Mar 01;(85):
pubmed: 24637495
Neuropsychopharmacol Rep. 2020 Dec;40(4):371-375
pubmed: 33089673
Science. 2014 Jun 6;344(6188):1173-8
pubmed: 24904169
Cell Rep. 2017 Dec 26;21(13):3637-3645
pubmed: 29281813
Brain Cogn. 2015 Apr;95:54-61
pubmed: 25682352